Alzheimer’s trial screening data links high amyloid levels with early stage disease
On Apr. 6, 2020, the first published data from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) study…
Redhill Biopharma announced first Covid-19 patient treated with Opaganib in Israel under Compassionate Use
On Apr. 6, 2020, RedHill Biopharma announced the first patient with confirmed coronavirus (COVID-19) diagnosis had been dosed…
RedHill Biopharma announced approval of Compassionate Use of Opaganib for COVID-19 in Italy
On Apr. 6, 2020, RedHill Biopharma announced it has received authorization from the Italian National Institute for Infectious…
COVID-19 | FDA | Therapeutics
FDA cleared Mesoblast IND for remestemcel use in COVID-19 ARDS patients
On Apr. 6, 2020, Mesoblast announced it had received clearance from the U.S. Food and Drug Administration (FDA)…
Mateon achieved milestone in development of OT-101, a phase 3 clinical drug candidate, against COVID-19
On Apr. 6, 2020, Mateon Therapeutics announced an update on its rapid antiviral response program targeting coronaviruses, initially…
New antiviral drug from Emory University heading into clinical trials for COVID-19 treatment
On Apr. 6, 2020, Emory’s Vaccine and Treatment Evaluation Unit (VTEU) announced its participation in a clinical trial…
Rice University established COVID-19 research fund
On Apr. 6, 2020, Rice University announced it had established a research accelerator fund to support projects –…
New IHME COVID-19 forecasts find lower hospital bed need, epidemics starting to peak confirms social distancing works
On Apr. 5, 2020, updated COVID-19 estimates from the Institute for Health Metrics and Evaluation (IHME) found that…
Minneapolis Heart Institute Foundation engaged in COVID-19 STEMI research study
On Apr. 6, 2020, the Minneapolis Heart Institute Foundation (MHIF) announced it was serving as the international coordinating…
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Influenza | Non-Profit Research | Therapeutics
Mesa Biotech to develop molecular point-of-care diagnostic test for novel Coronavirus (COVID-19)
On Apr. 4, 2020, Mesa Biotech announced the addition of the novel coronavirus (SARS-CoV-2) to its active influenza…
Mayo Clinic named national site for Convalescent Plasma Expanded Access Program
On Apr. 3, 2020, the FDA announced that the Mayo Clinic Mayo Clinic will be the lead institution…
OHSU launched in-house COVID-19 testing lab
On Apr. 3, 2020, Oregon Health & Science University (OHSU) announced that it had established an in-house COVID-19…
Mary and Ryan Finley donated $3 million to Legacy Health, OHSU to combat COVID-19
On Apr. 3, 2020, Oregon Health & Science University (OHSU) announced that Mary and Ryan Finley, moved by…
Penn Medicine launched trial to evaluate hydroxychloroquine to treat, prevent COVID-19
On Apr. 3, 2020, a trial led by the Perelman School of Medicine at the University of Pennsylvania…
Novartis announced plan to initiate clinical study of Jakavi in severe COVID-19 patients and establish international compassionate use program
On Apr. 2, 2020, Novartis announced plans to initiate a phase III clinical trial in collaboration with Incyte…
Trial drug significantly blocked early stages of COVID-19 in engineered human tissues
On Apr. 2, 2020, an international team led by University of British Columbia (UBC) researcher Dr. Josef Penninger…
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors of COVID-19
On Apr. 2, 2020, Vir Biotech and Alnylam Pharma announced an expansion to their broad multi-target existing collaboration…
Cerus announced inclusion of pathogen reduction technology in ISBT recommendations for preparation of COVID-19 convalescent plasma
On Apr. 2, 2020, Cerus announced that the International Society of Blood Transfusion (ISBT) Working Party on Global…
Biotechnology | COVID-19 | FDA | Therapeutics
Incyte initiated phase 3 clinical trial of Ruxolitinib (Jakafi) as treatment for patients with COVID-19 cytokine storm
On Apr. 2, 2020, Incyte announced it was working with the U.S. Food and Drug Administration (FDA) to…
Emergent BioSolutions partnered with U.S. Government to expedite development of plasma-derived therapy for COVID-19
On Apr. 2, 2020, Emergent BioSolutions announced it had entered into a formal partnership with the U.S. government…
COVID-19 | Therapeutics | WHO
CHF Solutions doubled production staff of Aquadex SmartFlow consoles due to hospital demand
On Apr. 2, 2020, CHF Solutions announced it has doubled the production staff that builds its next generation…
Fred Hutch team launched hunt for coronavirus antibodies
On Apr. 2, 2020, a team of scientists at Fred Hutchinson Cancer Research Center in Seattle began searching…
Biotechnology | Diagnostics | Disease | Genomics | Neurology | NIH | Therapeutics
Single mutation leads to big effects in autism-related gene
On Apr. 2, 2020, a study in Neuron offers clues to why autism spectrum disorder (ASD) is more…
Paratek Pharma announced BARDA funding for onshoring the manufacturing supply for NUZYRA (omadacycline)
On Apr. 1, 2020, Innovation Pharma announced BARDA had initiated funding to support the onshoring of Paratek manufacturing…
Early study of COVID-19 patients showed high mortality rate
On Apr. 1, 2020, a University of Washington Medicine led study of 24 of the most critically ill…
Fujifilm announced start of phase III clinical trial of influenza antiviral drug ‘Avigan Tablet’ on COVID-19 patients
On Mar. 31, 2020, FUJIFILM announced initiation of a phase III clinical trial to evaluate the safety and…
Philips to fulfill contract with the HHS for the delivery of 10,000 Trilogy Universal units with accelerated delivery
On Mar. 31, 2020, Philips announced that it was fully committed to fulfill the contract with the U.S….
VIVUS accelerated launch of telemedicine and remote monitoring modules to facilitate ‘Social Distancing’
On Mar. 31, 2020, VIVUS announced the accelerated launch of the telemedicine and remote monitoring modules of the…
Sorrento announced research testing agreement with University of Texas for preclinical testing of COVID-19 therapeutic product candidates
On Mar. 31, 2020, Sorrento announced it had entered into a research testing agreement with The University of…
Kleo Pharmaceuticals announced research collaboration with Green Cross LabCell to develop COVID-19-targeting allogeneic NK Cell combination therapy
On Mar. 31, 2020, Kleo Pharmaceuticals announced it had entered into a research collaboration with South Korea -based…